2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)

Background

VTE is a significant complication in oncology and one of the primary causes of cancer-related mortality. Few studies have addressed VTE in pts with NET, with an estimated incidence of 7.5%. Nevertheless, there is no evidence from large datasets. In the present study, we analyzed the incidence and treatment of VTE in NET.

Methods

Consecutive pts with gastroenteropancreatic (GEP) and thoracic NET treated in our institution between 2017 and 2018 were selected to study the incidence of VTE including deep vein thrombosis (DVT), pulmonary embolisms (PE) and splanchnic venous thrombosis (SVT). Information regarding clinical characteristics, follow up and VTE treatment were collected.

Results

320 pts (55% female) were included in the analysis (40.6% pancreatic, 27.1% small intestine, 9.3% lung). 65 pts presented any thrombotic event (20.3%), and 23 were directly related to TNE (7.1%). Characteristics of patients with TNE-related VTE are enlisted in the table. The leading cause of SVT was splenic vein thrombosis (SPLVT). All cases that started anticoagulant therapy were treated with low-molecular-weight heparin (100%) and most of them indefinitely (53.8%). All cases that did not receive anticoagulant therapy were splenic vein thrombosis, due to physician decision. Any complication related to anticoagulant therapy was described in 3 pts (13%). No cases of VTE-related death were found.

Table: 2151P

Clinical characteristics of patients with NET-related VTE

Conclusions

NET-related VTE appears in 7.1% of pts with NET. Most common profile is a male with advanced pancreatic neuroendocrine neoplasm and SPLVT. Impact on prognosis and the need for anticoagulant therapy remains controversial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

J. Hernando: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. A. Garcia Alvarez: Financial Interests, Personal, Advisory Board: ADACAP (Novartis); Other, Expenses (Travel, Congress inscription): Advanz, Eisai, Ipsen, ADACAP (Novartis). J. Capdevila Castillon: Financial Interests, Personal, Invited Speaker: Novartis, Novartis, Pfizer, Ipsen, Exelis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Merck Serono; Financial Interests, Personal, Advisory Board: Pfizer, Ipsen, Exelis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Merck Serono, Esteve, ITM; Financial Interests, Personal, Research Grant: Novartis, Pfizer, AstraZeneca, Advanced Accelerator Applications, Eisai, Bayer. All other authors have declared no conflicts of interest.